氨基酶N:在药物化学中是一个多功能和有前途的标
1Department of Chemical Drugs, Faculty of Pharmacy, Masaryk University Palackého 1946/1 Brno Czech Republic farsao@pharm.muni.cz.
RSC advances
|July 24, 2025
概括
氨基酶N (APN) 是一种多功能酶,在癌症,病毒进入和炎症中发挥作用. APN 抑制剂对各种疾病具有有前途的治疗作用,目前正在研究开发新药.
科学领域:
- 生物化学 生物化学
- 酶学 是一种酶学.
- 分子生物学分子生物学
背景情况:
- 氨基酶N (APN) 是一种金属蛋白酶,具有多样化,往往非催化作用的功能,因此被归类为月光酶.
- APN在生物过程中发挥关键作用,包括致癌,血管生成,病毒进入 (作为某些冠状病毒的受体) 和皮肤炎症.
- 该酶参与调节蛋白的新陈代谢,如神经,突出其治疗相关性.
研究的目的:
- 为提供阿米诺酶N (APN) 多方面的功能提供了全面的概述.
- 探索APN在各种疾病病理学的影响.
- 审查现有的APN抑制剂,并确定抑制剂开发的有希望的未来方向.
主要方法:
- 关于N. Aminopeptidase的科学出版物的文献综述
- 对已知的APN功能和参与疾病的分析.
- 对针对APN的当前和潜在治疗策略的调查.
主要成果:
- 除了酶性活动之外,APN还表现出广泛的功能.
- APN与重要的病理过程有关,包括癌症和病毒感染.
- 已经研究了几种APN抑制剂,如贝斯塔丁和托塞多斯塔特,证明了部分治疗成功.
结论:
- 氨基酶N是一种关键酶,对人类健康和疾病有广泛的影响.
- 准APN为一系列疾病提供了显著的治疗潜力.
- 对新型APN抑制剂的进一步研究是有必要的,以改善治疗策略.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Preparation of Amines: Reductive Amination of Aldehydes and Ketones
3.1K
Carbonyl compounds and primary amines undergo reductive amination first to produce imines, followed by secondary amines in the same reaction mixture, using selective reducing agents like sodium cyanoborohydride or sodium triacetoxyborohydride. Reductive amination produces different degrees of substitution of amines depending on the starting amine substrate.
3.1K
Allosteric Proteins-ATCase
5.9K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.9K
Ligand Binding and Linkage
4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K


